Use and cost of disease-modifying therapies by Sonya Slifka Study participants: has anything really changed since 2000 and 2009?

BACKGROUND: Disease-modifying therapies benefit individuals with relapsing forms of multiple sclerosis, but their utility remains unclear for those without relapses. OBJECTIVE: To determine disease-modifying therapy use and costs in 2009, compare use in 2009 and 2000, and examine compliance with evi...

Descripción completa

Detalles Bibliográficos
Autores principales: Minden, Sarah L, Kinkel, R Philip, Machado, Helene T, Levin, Jonathan S, Rosenthal, Meredith B, Iezzoni, Lisa I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Original Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6385335/
https://www.ncbi.nlm.nih.gov/pubmed/30815276
http://dx.doi.org/10.1177/2055217318820888

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6385335/
https://www.ncbi.nlm.nih.gov/pubmed/30815276
http://dx.doi.org/10.1177/2055217318820888

Ejemplares similares